PT  - JOURNAL ARTICLE
AU  - Aamodt, Anne Hege
AU  - Ueland, Thor
AU  - Boldingh, Marion I.
AU  - Bezgal, Burcu
AU  - Argren, Maria
AU  - Dunne, Cecilia Adele
AU  - Otterdal, Kari
AU  - Gregersen, Ida
AU  - Bjerkeli, Vigdis
AU  - Michelsen, Annika Elisabet
AU  - Husøy, Andreas
AU  - Morsund, Åse Hagen
AU  - Devik, Kristina
AU  - Poole, Anne Christine
AU  - Gjendemsjø, Kristine
AU  - Schlüter, Katrin
AU  - Mathisen, Sara Maria
AU  - Aalstad-Johansen, Mari
AU  - Skattør, Thor
AU  - Sønnervik, Julie
AU  - Boye, Birgitte
AU  - Popperud, Trine Haug
AU  - Høgestøl, Einar August
AU  - Harbo, Hanne Flinstad
AU  - Lund-Johansen, Fridtjof
AU  - Aukrust, Pål
AU  - Tronvik, Erling
AU  - Dahl, Tuva Børresdatter
AU  - Halvorsen, Bente E.
TI  - Altered amyloid plasma profile in patients with disabling headaches after SARS-CoV-2 infection and vaccination
AID  - 10.1101/2024.10.19.24315794
DP  - 2024 Jan 01
TA  - medRxiv
PG  - 2024.10.19.24315794
4099  - http://medrxiv.org/content/early/2024/10/22/2024.10.19.24315794.short
4100  - http://medrxiv.org/content/early/2024/10/22/2024.10.19.24315794.full
AB  - Background and objectives: New onset persistent headache has been reported following acute COVID-19 disease and to some degree also after SARS-CoV-2 vaccination. Still, the mechanisms for these headache types are unclear. The purpose of this study was to assess levels of amyloid related biomarkers in patients with persistent headache after COVID-19 and SARS-CoV-2 vaccine. Methods: In this prospective observational cohort, patients with severe headache as the dominating symptom after COVID-19 disease (n=29) and SARS-CoV-2 vaccination (n=31), had neurological assessments with reassessments after 6 months. Plasma levels of amyloid precursor protein (APP), pregnancy zone protein (PZP), cathepsin L1 (CTSL) and serum Amyloid A (SAA1) were measured by ELISA in relation to levels in healthy controls (n=16). Results: We found a strong and persistent upregulation of APP in patients with headache after COVID-19 as compared to the two other groups. At both inclusion and after 6 months APP levels were also increased in those with accompanying cognitive symptoms. In contrast, plasma levels of PZP were elevated in both headache groups as compared to healthy controls at inclusion and after 6 months follow-up, but with no relation to cognitive symptoms. CTSL was only elevated in those with COVID-19 associated headache at baseline, whereas SAA1 showed levels comparable in all groups. Conclusion: Altered plasma levels of soluble markers potentially reflecting changes in amyloid processing was found in patients with persistent headache after SARS-CoV-2 vaccine and particular in those with persistent headache after COVID-19 disease where we also found some association with cognitive symptoms.Competing Interest StatementThe authors have declared no competing interest.Clinical Protocolshttps://www.clinicaltrials.gov/study/NCT04576351?term=NCT04576351&rank=1https://www.clinicaltrials.gov/study/NCT05235776?term=covaxhead&rank=1Funding StatementStudy funding: Supported by Oslo University Hospital and the Southern and Eastern Norway Regional Health Authority (2021051).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:This study was conducted in accordance with the Helsinki Declaration as revised in 2013. Ethical approval for this study was obtained from The Norwegian South-Eastern Ethical Committee (152727 NNC, 351097 CovaxHEAD). Written informed consent was obtained from all subjects before inclusion into the study.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).Yes I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesAll data produced in the present study are available upon reasonable request to the authors